礼来：替尔泊肽2025年销量超365亿美元，2026年业绩指引预计达800亿至830亿美元

Core Insights - The company reported a global revenue of $19.292 billion for the year 2025, representing a 43% increase compared to $13.533 billion in 2024, driven primarily by the sales growth of Mounjaro and Zepbound [1] - The net profit according to GAAP was $6.636 billion, a 50% year-over-year increase, with earnings per share (EPS) of $7.39, also reflecting a 51% increase, including $0.52 in IPR&D expenses [1] - Non-GAAP net profit was $6.771 billion, a 41% increase year-over-year, with an EPS of $7.54, marking a 42% increase, similarly including $0.52 in IPR&D expenses [1] - The company provided guidance for 2026, expecting revenue to reach between $80 billion and $83 billion, with non-GAAP EPS projected at $33.50 to $35.00 [1]